Medline Inc. Class A common stock MDLN

Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.

• GlobeNewswire Inc. 1 oct

  Bragar Eagel & Squire, P.C. is Investigating Medline Inc. on Behalf of Medline Stockholders and Encourages Investors to Contact the Firm

  Law firm Bragar Eagel & Squire is investigating Medline Inc. for potential securities law violations following FDA warning letters regarding manufacturing practice violations. The company's stock declined 7.2% on June 2, 2026 after FDA warnings and another 12.8% on August 5, 2026 after the company disclosed earnings losses from remediation efforts including product recalls.

  

• GlobeNewswire Inc. 29 sept

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

  Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and another 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.

  

• GlobeNewswire Inc. 28 sept

  MEDLINE INC. INVESTIGATION: MDLN Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  Law firm Kirby McInerney LLP is investigating Medline Inc. for potential federal securities law violations following an FDA warning letter in June 2026 detailing significant manufacturing practice violations. The company's stock declined 7.2% on the FDA announcement and another 12.8% in August after Medline disclosed earnings losses from remediation efforts including product recalls.

  

• GlobeNewswire Inc. 7 ago

  NASDAQ: MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

  Kessler Topaz Meltzer & Check, LLP is investigating potential securities law violations by Medline Inc. following significant FDA violations related to manufacturing quality standards and microbial contamination. The company's stock fell over 7% after the FDA warning letter and dropped an additional 12% following disappointing Q2 results and lowered full-year guidance.

  

• GlobeNewswire Inc. 7 jul

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLN

  Pomerantz LLP is investigating potential securities fraud claims against Medline Industries following an FDA warning letter on June 2, 2026, citing significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals. The announcement triggered a 7.16% stock price decline ($2.56 per share) to $33.19.